Humacyte Inc (NASDAQ: HUMA) on Friday, plunged -7.97% from the previous trading day, before settling in for the closing price of $2.51. Within the past 52 weeks, HUMA’s price has moved between $1.15 and $9.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 42.43% over the past five years. The company achieved an average annual earnings per share of 79.88%. With a float of $125.45 million, this company’s outstanding shares have now reached $155.12 million.
Let’s look at the performance matrix of the company that is accounted for 220 employees. In terms of profitability, gross margin is 23.12%, operating margin of -1433.23%, and the pretax margin is -1002.79%.
Humacyte Inc (HUMA) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Humacyte Inc is 19.13%, while institutional ownership is 39.93%. The most recent insider transaction that took place on Apr 14 ’25, was worth 9,999. In this transaction Chief Commercial Officer of this company bought 6,493 shares at a rate of $1.54, taking the stock ownership to the 22,018 shares. Before that another transaction happened on Apr 10 ’25, when Company’s CFO and Chief Corp. Deve. Off. bought 20,000 for $1.53, making the entire transaction worth $30,600. This insider now owns 40,600 shares in total.
Humacyte Inc (HUMA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 79.88% per share during the next fiscal year.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Humacyte Inc (HUMA) is currently performing well based on its current performance indicators. A quick ratio of 3.28 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 689.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.69, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.25 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
Humacyte Inc (NASDAQ: HUMA) saw its 5-day average volume 5.8 million, a positive change from its year-to-date volume of 3.73 million. As of the previous 9 days, the stock’s Stochastic %D was 52.21%.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 40.14%, which indicates a significant increase from 32.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.19 in the past 14 days, which was lower than the 0.22 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.18, while its 200-day Moving Average is $3.57. Nevertheless, the first resistance level for the watch stands at $2.46 in the near term. At $2.60, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.71. If the price goes on to break the first support level at $2.21, it is likely to go to the next support level at $2.10. Assuming the price breaks the second support level, the third support level stands at $1.96.
Humacyte Inc (NASDAQ: HUMA) Key Stats
Market capitalization of the company is 358.32 million based on 155,119K outstanding shares. Right now, sales total 0 K and income totals -148,700 K. The company made 520 K in profit during its latest quarter, and 39,140 K in sales during its previous quarter.
